iShares Neuroscience and Healthcare ETF
Price through Oct 27, 2026 · Flows through Oct 26, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 27, 2026. Holdings snapshot retrieved Oct 27, 2026.
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
IBRN price
Table
| Date | IBRN close |
|---|---|
| Sep 28, 2026 | $33.47 |
| Sep 29, 2026 | $33.20 |
| Sep 30, 2026 | $33.27 |
| Oct 1, 2026 | $32.87 |
| Oct 2, 2026 | $32.55 |
| Oct 5, 2026 | $32.41 |
| Oct 6, 2026 | $32.04 |
| Oct 7, 2026 | $31.86 |
| Oct 8, 2026 | $31.39 |
| Oct 9, 2026 | $31.75 |
| Oct 12, 2026 | $31.43 |
| Oct 13, 2026 | $30.30 |
| Oct 14, 2026 | $29.96 |
| Oct 15, 2026 | $30.72 |
| Oct 16, 2026 | $29.97 |
| Oct 19, 2026 | $30.79 |
| Oct 20, 2026 | $31.84 |
| Oct 21, 2026 | $31.51 |
| Oct 22, 2026 | $31.75 |
| Oct 23, 2026 | $31.36 |
| Oct 26, 2026 | $31.60 |
| Oct 27, 2026 | $32.24 |
Daily net flows, 1M
Net inflow over the range: +$0M
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Sep 28 | $0 |
| Sep 29 | $0 |
| Sep 30 | −$7.2K |
| Oct 1 | $7.2K |
| Oct 2 | $0 |
| Oct 5 | $0 |
| Oct 6 | $0 |
| Oct 7 | $43.2K |
| Oct 8 | $50.6K |
| Oct 9 | −$93.8K |
| Oct 12 | $84.9K |
| Oct 13 | −$79.6K |
| Oct 14 | $0 |
| Oct 15 | −$129.7K |
| Oct 16 | $125.5K |
| Oct 19 | $0 |
| Oct 20 | $0 |
| Oct 21 | $0 |
| Oct 22 | $0 |
| Oct 23 | $0 |
| Oct 26 | $0 |
Money keeps arriving — +$1K of net inflows over the past month, while the price has returned -0.2% so far this year. At 0.47% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | NEUNEWMARKET | 2.35% | $875.42 | -0.3% | ||
| 2 | BIIBBIOGEN | 5.59% | $252.73 | +0.2% | ||
| 3 | ALKSALKERMES | 4.66% | $44.32 | -0.3% | ||
| 4 | NBIXNEUROCRINE BIOSCIENCES | 4.51% | $146.00 | +0.1% | ||
| 5 | EWTXEDGEWISE THERAPEUTICS | 4.48% | $39.53 | +0.9% | ||
| 6 | PTCTPTC THERAPEUTICS | 4.30% | $62.09 | +1.7% | ||
| 7 | ARGXARGENX SE | 4.17% | $882.48 | +1.5% | ||
| 8 | SRRKSCHOLAR ROCK HOLDING | 3.69% | $42.49 | +1.9% | ||
| 9 | PRAXPRAXIS PRECISION MEDICINES | 3.53% | $267.59 | +0.1% | ||
| 10 | DNTHMAGENTA THERAPEUTICS INC | 3.49% | $79.52 | +0.2% | ||
| 11 | ACADACADIA PHARMACEUTICALS | 3.46% | $20.17 | +2.2% | ||
| 12 | SUPNSUPERNUS PHARMACEUTICALS | 3.44% | $40.96 | +0.5% | ||
| 13 | DYNDYNE THERAPEUTICS | 3.16% | $16.94 | +7.8% | ||
| 14 | BHVNBIOHAVEN | 2.77% | $15.29 | +5.8% | ||
| 15 | AXGNAXOGEN | 3.09% | $37.46 | -1.5% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 54Sector weights
- Health Care98.72%
- Information Technology1.11%
- Cash and/or Derivatives0.18%
Show as table
| Item | Value (%) |
|---|---|
| Health Care | 98.72% |
| Information Technology | 1.11% |
| Cash and/or Derivatives | 0.18% |
Country weights
- United States74.85%
- Belgium4.17%
- Korea (South)3.55%
- Denmark3.25%
- Sweden3.12%
- Australia2.37%
- Switzerland2.12%
- Japan2.08%
Show as table
| Item | Value (%) |
|---|---|
| United States | 74.85% |
| Belgium | 4.17% |
| Korea (South) | 3.55% |
| Denmark | 3.25% |
| Sweden | 3.12% |
| Australia | 2.37% |
| Switzerland | 2.12% |
| Japan | 2.08% |
| 1 week | +2.3% |
| 1 month | -3.3% |
| 3 months | -14.5% |
| 6 months | -6.5% |
| YTD | -0.2% |
| 1 year | +6.8% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | +$1K |
| 3 months | +$2M |
| YTD | +$2M |
| 1 year | +$2M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Show as table
| Label | Value ($) |
|---|---|
| Oct | $0 |
| Nov | $0 |
| Dec | $0 |
| Jan | $0 |
| Feb | $0 |
| Mar | $0 |
| Apr | $0 |
| May | $0 |
| Jul | −$44 |
| Aug | $2M |
| Sep | −$60.2K |
| Oct | $8.3K |
The top holding is 5.6% of the book; the top ten carry 42%. Spread across 73+ names, it behaves like roughly 33 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| AXGN AXOGEN | $2M | $1M |
| PRAX PRAXIS PRECISION MEDICINES | $1M | $789,344 |
| BIIB BIOGEN | $667,178 | $687,416 |
| CAPR CAPRICOR THERAPEUTICS | $605,267 | $268,805 |
| ARGX ARGENX SE | $62,652 | $136,882 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBRN on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $40.7B | +$609M | -44bp on fee · 6430× the assets · +$609M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -44bp on fee · 2902× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -43bp on fee · 5125× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$51M | -43bp on fee · 3750× the assets · +$51M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -43bp on fee · 2939× the assets · +$412M in over the month | Head-to-head |